Communications biologyJul 8, 2026

Engineered carriers deliver mRNA to skin for healing and regeneration

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jul 9, 2026

Abstract

RNA-BEVs induced transient protein expression throughout reconstructed epidermis after topical administration.

Biologically Engineered Vectors (BEVs) are defined as delivery particles created through genetic or cellular engineering.
RNA-BEVs were developed specifically for the purpose of delivering mRNA to the skin.
Functional mRNA was efficiently delivered to keratinocytes using RNA-BEVs.
RNA-BEVs improved the histological quality of skin repair compared to traditional mRNA-loaded lipid nanoparticles in a diabetic rat wound model.
This approach may provide a new method for localized transient RNA delivery in regenerative medicine.

Simplified

Messenger RNA therapeutics offer transient protein expression without altering the cellular genome, making them attractive for regenerative medicine, but efficient and safe delivery to the skin remains a major challenge. Lipid nanoparticles have transformed RNA delivery yet can remain limited in skin by tissue accessibility, formulation constraints and local tissue responses. Here we define Biologically Engineered Vectors (BEVs) as biologically assembled delivery particles generated through genetic or cellular engineering to transport therapeutic nucleic acids, and we develop RNA-BEVs as a platform for topical mRNA delivery. RNA-BEVs efficiently delivered functional mRNA to keratinocytes, induced transient protein expression throughout reconstructed epidermis after topical administration, and improved the histological quality of repair relative to mRNA-loaded lipid nanoparticles in a diabetic rat wound model. These findings establish RNA-BEVs as a biologically assembled platform for localized transient RNA delivery and skin regeneration.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Competing interests: N.G. and H.P. are inventors on a pending patent application assigned to GEG Tech covering RNA sequences relevant to this work. N.G. is also an inventor on the granted US patent US10308955B2, Transient expression vectors, preparation and uses thereof (United States), which covers reverse-transcriptase mutations relevant to the RNA-BEV technology described here. The remaining authors declare no competing interests.

PubMed

Engineered carriers deliver mRNA to skin for healing and regeneration

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief